Alopecia Areata(AA)NR3C1 and AANCT07455708
Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata
An observational study of Alopecia Areata(AA), run by Benha University at 1 site in Egypt.
Trial summary
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Alopecia Areata(AA)
- How many people
- 120 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2023to 1 Dec 2024
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study will include 60 patients clinically diagnosed with alopecia areata and 60 age- and sex-matched healthy controls recruited from the same geographic area.
Who may be able to join
- Clinically diagnosed alopecia areata
- Age ≥ 18 years
- Both sexes
- Willingness to participate and provide informed consent
- Apparently healthy individuals
- No history of autoimmune disease
- Age- and sex-matched to cases
- Provided informed consent
Who cannot join
- Presence of other autoimmune or inflammatory diseases
- Current systemic immunosuppressive therapy
- Pregnancy or lactation
- Refusal to participate
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Glucocorticoid Receptor Gene Polymorphism in Alopecia Areata
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.
- Conditions
- Alopecia Areata(AA)
- Keywords
- Alopecia areata, Glucocorticoid, polymorphism
- Medical subject headings
- Alopecia Areata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Alopecia Areata Patients | Participants diagnosed clinically with alopecia areata (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. Disease severity will be assessed using SALT score. | |
| Group 2: Healthy Controls | Age- and sex-matched healthy individuals without autoimmune disease (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution of NR3C1 rs41423247 Genotypes and Alleles
Comparison of genotype and allele frequencies of NR3C1 rs41423247 polymorphism between alopecia areata patients and healthy controls.
Measured: Baseline
Secondary outcomes (1)
Association Between NR3C1 rs41423247 Polymorphism and Disease Severity
Correlation between NR3C1 rs41423247 genotypes and Severity of Alopecia Tool (SALT) score in patients with alopecia areata.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start1 Nov 2023
- Primary completion1 Nov 2024
- Study completion1 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alopecia Areata(AA)Studies of the same condition, open and under way.
- More trials run by Benha UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 120 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Benha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, karem Taha ibrahim khalil, Benha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07455708
- Sponsor's protocol ID
- Ms 10.9.2023
- Other IDs
- Benha faulty of medicine
- Acronym
- NR3C1 and AA
- Status last verified
- Mar 2026
- First submitted
- 3 Mar 2026
- Last updated
- 6 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Glucocorticoid Receptor Gene Polymorphism in Alopecia Areata
- ClinicalTrials.gov ID
- NCT07455708
- Acronym / sponsor ID
- NR3C1 and AA / Ms 10.9.2023
- Conditions
- Alopecia Areata(AA)
- Keywords
- Alopecia areata, Glucocorticoid, polymorphism
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Benha UniversityUniversity, hospital or other
- Study start
- 1 Nov 2023 (actual)
- Primary completion
- 1 Nov 2024 (actual)
- Study completion
- 1 Dec 2024 (actual)
- First posted
- 6 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response. The rs41423247 polymorphism (BclI) may influence glucocorticoid sensitivity and disease activity. This study aims to investigate the association between NR3C1 rs41423247 polymorphism and susceptibility to alopecia areata and to evaluate its correlation with disease severity using the Severity of Alopecia Tool (SALT) score.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1: Alopecia Areata Patients | – | –Participants diagnosed clinically with alopecia areata (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. Disease severity will be assessed using SALT score. |
| Group 2: Healthy Controls | – | –Age- and sex-matched healthy individuals without autoimmune disease (n = 60). Peripheral blood samples will be collected for genetic analysis of NR3C1 rs41423247 polymorphism. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include 60 patients clinically diagnosed with alopecia areata and 60 age- and sex-matched healthy controls recruited from the same geographic area.
Key inclusion criteria (8 listed)
- Clinically diagnosed alopecia areata
- Age ≥ 18 years
- Both sexes
- Willingness to participate and provide informed consent
- Apparently healthy individuals
Key exclusion criteria (4 listed)
- Presence of other autoimmune or inflammatory diseases
- Current systemic immunosuppressive therapy
- Pregnancy or lactation
- Refusal to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Distribution of NR3C1 rs41423247 Genotypes and Alleles
Time frame: Baseline
Comparison of genotype and allele frequencies of NR3C1 rs41423247 polymorphism between alopecia areata patients and healthy controls.
1 secondary outcome
Association Between NR3C1 rs41423247 Polymorphism and Disease Severity
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Alopecia Areata(AA)
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Active, not recruitingPhase 1/2
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
Alopecia Areata (AA)
RecruitingPhase 1
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
Alopecia Areata(AA)
RecruitingObservational study
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Alopecia Areata
Active, not recruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alopecia Areata(AA), run by Benha University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution of NR3C1 rs41423247 Genotypes and Alleles (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2026.